Additional investigation of CatL inhibitors in vitro and in vivo will not only contribute to optimizationof an anticoronaviral drug but also increase the level of preparednessto deal with cathepsin-dependent viral infections and potentiallyother diseases of high relevance in the future. The gene discussed is CTSL; the disease is viral infectious disease.